Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445198 | 0.83 | CHRNA1 (0.51) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL29697723 | 0.80 | CHRNB4 (0.63) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL7373184 | 0.77 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL427054 | 0.77 | HRH3 (0.44) | — | |
| SCHEMBL13452624 | 0.77 | HTR1D (0.49) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL23886224 | 0.76 | SSTR4 (0.39) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL25181388 | 0.76 | SSTR4 (0.39) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL16453454 | 0.76 | KDM4E (0.44) | — | |
| SCHEMBL8441392 | 0.76 | CHRNB1 (0.63) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL15086907 | 0.76 | UHRF1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CHRNB2 3416/4885CHRNA4 3387/4885CHRNB1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.